Swiss National Bank Decreases Stock Position in Lantheus Holdings, Inc. $LNTH

Swiss National Bank lowered its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.0% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 130,754 shares of the medical equipment provider’s stock after selling 4,000 shares during the period. Swiss National Bank’s holdings in Lantheus were worth $10,704,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Quarry LP raised its position in shares of Lantheus by 2,350.0% in the first quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock valued at $48,000 after buying an additional 470 shares during the last quarter. EMC Capital Management purchased a new stake in Lantheus during the 2nd quarter valued at about $93,000. Parkside Financial Bank & Trust raised its holdings in Lantheus by 20.2% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,264 shares of the medical equipment provider’s stock valued at $103,000 after acquiring an additional 212 shares during the last quarter. AlphaQuest LLC lifted its stake in Lantheus by 252.5% in the 1st quarter. AlphaQuest LLC now owns 1,653 shares of the medical equipment provider’s stock worth $161,000 after purchasing an additional 1,184 shares in the last quarter. Finally, Bayforest Capital Ltd purchased a new position in Lantheus in the 1st quarter worth approximately $180,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Up 0.4%

Shares of NASDAQ:LNTH opened at $59.00 on Friday. The company has a market capitalization of $3.91 billion, a price-to-earnings ratio of 15.69 and a beta of 0.04. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $111.29. The business has a 50-day moving average price of $54.59 and a 200 day moving average price of $64.26. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. The company had revenue of $92.51 million for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. Sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analyst Weigh In

LNTH has been the subject of several recent research reports. JMP Securities cut their price target on Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a report on Thursday, August 7th. Truist Financial reaffirmed a “hold” rating and issued a $61.00 target price (down from $63.00) on shares of Lantheus in a research note on Monday, November 10th. Mizuho reduced their price target on Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, August 7th. TD Cowen dropped their price objective on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, September 15th. Finally, Weiss Ratings downgraded shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $74.17.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.